For (non-fatal) stroke, 3 out of 4 SGLT-2 I and 2 out of 4 DPP-4 I studies provided an estimated power > 80% to detect significances differences between active drug and placebo treatment amounting to > 15% (Fig. 3). This evidence concerns the gene SLC5A2 and stroke disorder.